Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan; Department of Infectious Diseases, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Vaccine. 2022 May 11;40(22):3018-3026. doi: 10.1016/j.vaccine.2022.04.033. Epub 2022 Apr 11.
We have reported the vaccine effectiveness of inactivated influenza vaccine in children aged 6 months to 15 years between the 2013/14 and 2018/19 seasons. Younger (6-11 months) and older (6-15 years old) children tended to have lower vaccine effectiveness. The purpose of this study is to investigate whether the recent vaccine can be recommended to all age groups.
The overall adjusted vaccine effectiveness was assessed from the 2013/14 until the 2020/21 season using a test-negative case-control design based on rapid influenza diagnostic test results. Vaccine effectiveness was calculated by influenza type and by age group (6-11 months, 1-2, 3-5, 6-12, and 13-15 years old) with adjustments including influenza seasons.
A total of 29,400 children (9347, 4435, and 15,618 for influenza A and B, and test-negatives, respectively) were enrolled. The overall vaccine effectiveness against influenza A, A(H1N1)pdm09, and B was significant (44% [95% confidence interval (CI), 41-47], 63% [95 %CI, 51-72], and 37% [95 %CI, 32-42], respectively). The vaccine was significantly effective against influenza A and B, except among children 6 to 11 months against influenza B. The age group with the highest vaccine effectiveness was 1 to 2 years old with both influenza A and B (60% [95 %CI, 55-65] and 52% [95 %CI, 41-61], respectively). Analysis for the 2020/21 season was not performed because no cases were reported.
This is the first report showing influenza vaccine effectiveness by age group in children for several seasons, including immediately before the coronavirus disease (COVID-19) era. The fact that significant vaccine effectiveness was observed in nearly every age group and every season shows that the recent vaccine can still be recommended to children for the upcoming influenza seasons, during and after the COVID-19 era.
我们已经报告了 2013/14 至 2018/19 季节期间 6 个月至 15 岁儿童中灭活流感疫苗的疫苗效力。年龄较小(6-11 个月)和较大(6-15 岁)的儿童疫苗效力往往较低。本研究的目的是调查最近的疫苗是否可以推荐给所有年龄段。
使用基于快速流感诊断测试结果的病例对照设计,评估了 2013/14 年至 2020/21 年的总体调整后疫苗效力。通过流感类型和年龄组(6-11 个月、1-2 岁、3-5 岁、6-12 岁和 13-15 岁)计算疫苗效力,并进行了流感季节的调整。
共纳入 29400 名儿童(分别为流感 A、B 和测试阴性的 9347、4435 和 15618 例)。流感 A、A(H1N1)pdm09 和 B 的总体疫苗效力均有显著效果(44%[95%置信区间(CI),41-47]、63%[95%CI,51-72]和 37%[95%CI,32-42])。流感 A 和 B 对疫苗有显著效果,但 6-11 个月的儿童对 B 型流感无效。疫苗效力最高的年龄组是 1 至 2 岁,对流感 A 和 B 的效力分别为 60%[95%CI,55-65]和 52%[95%CI,41-61]。由于没有报告病例,因此未对 2020/21 季节进行分析。
这是第一项按年龄组报告儿童几个季节流感疫苗效力的报告,包括在冠状病毒病(COVID-19)时代之前。几乎每个年龄组和每个季节都观察到显著的疫苗效力这一事实表明,即使在 COVID-19 时代,最近的疫苗仍可推荐给儿童用于即将到来的流感季节。